Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development, commercialization, and lifecycle management of therapies for rare and orphan neuromuscular and neurological diseases. The company operates within the biotechnology and specialty pharmaceuticals industries, with a business model centered on acquiring or developing late-stage or approved products that address high-unmet-need patient populations. Its revenue is primarily generated from the commercialization of FDA-approved therapies in the United States.
Catalyst’s core products target rare neuromuscular disorders, with a strategic emphasis on diseases with limited or no approved treatment options. The company’s flagship product, FIRDAPSE®, is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients. In 2023, Catalyst expanded its portfolio with AGAMREE® (vamorolone), approved for Duchenne muscular dystrophy (DMD). Founded in 2002, the company initially pursued drug development internally but evolved into a commercial-stage company following the FDA approval of FIRDAPSE in 2018, marking a pivotal shift toward sustainable revenue generation.
Business Operations
Catalyst operates primarily as a commercial-stage pharmaceutical company, with revenue derived from product sales, predominantly in the United States. Its main operating segments consist of the commercialization and lifecycle management of approved therapies for rare diseases. FIRDAPSE® represents a significant revenue driver, supported by a focused sales and medical affairs infrastructure targeting neuromuscular specialists and treatment centers.
The company controls commercial rights to its key products in the U.S. market and leverages a lean operating structure that outsources manufacturing while retaining regulatory, marketing, and distribution oversight. Catalyst conducts no large-scale in-house manufacturing and instead relies on qualified third-party manufacturers. The company also operates through international subsidiaries, including Catalyst Pharmaceuticals Ireland Limited, to support global supply chain and regulatory functions.
Strategic Position & Investments
Catalyst’s strategic direction emphasizes portfolio expansion through acquisitions, licensing agreements, and selective internal development of late-stage assets for rare diseases. A major strategic investment was the acquisition of U.S. commercialization rights to AGAMREE®, significantly broadening the company’s addressable patient population and reinforcing its focus on neuromuscular disorders. This acquisition marked Catalyst’s entry into the Duchenne muscular dystrophy market, a substantially larger rare disease segment than LEMS.
The company continues to evaluate opportunities in adjacent rare neurological and neuromuscular indications, prioritizing assets with established clinical data and clear regulatory pathways. Catalyst’s strategy favors disciplined capital allocation, focusing on assets that can leverage its existing commercial infrastructure rather than early-stage research platforms. Data inconclusive based on available public sources regarding any undisclosed pipeline assets beyond publicly announced programs.
Geographic Footprint
Catalyst is headquartered in Coral Gables, Florida, and its commercial operations are primarily concentrated in North America, with a strong focus on the United States market. The majority of its revenue is generated domestically through U.S. product sales to specialty pharmacies, hospitals, and treatment centers.
Internationally, Catalyst maintains a limited operational footprint, primarily supporting regulatory, supply chain, and corporate functions rather than direct commercial sales. Through its subsidiaries, the company has an operational presence in Europe, mainly for administrative and logistical purposes, but it does not currently report significant ex-U.S. commercial revenue.
Leadership & Governance
Catalyst is led by an experienced executive team with backgrounds in rare disease commercialization, regulatory affairs, and pharmaceutical operations. The leadership philosophy emphasizes disciplined growth, operational efficiency, and a patient-centric approach to rare disease treatment, with strategic decisions guided by long-term value creation and regulatory rigor.
Key executives include:
- Richard J. Daly – President and Chief Executive Officer
- Brian G. McEnany – Chief Financial Officer
- Steve Miller – Chief Commercial Officer
- Gary Ingenito – Chief Medical Officer
- Amit Bhalla – Chief Legal Officer and Corporate Secretary
The company operates under a board-governed structure aligned with public company standards and regulatory requirements, with oversight of strategy, risk management, and executive compensation.